TP53 and acute myeloid leukemia: Multivariate analysis of the chemotherapy‐only group was consistent with previous studies in that older age (≥60 years), more BM blasts (≥70%), mutations in TP53 and DNMT3A also independently contributed to shorter EFS and OS.25, 26, 27, 28 The effect of high DDIT4 expression on survival was not reproduced in the allo‐HSCT group, whereas WBC count ≥ 15 × 109/L, FLT3‐ITD and TP53 mutation were associated with poor OS or EFS, suggesting that allo‐HSCT could ameliorate the adverse prognostic effect of high DDIT4 expression in AML.